Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial
Abstract
Paclitaxel embedded in cationic liposomes (EndoTAG (TM)-1; ET) is an innovative agent targeting tumor endothelial cells. This randomized controlled phase II trial evaluated the safety and efficacy of ET in combination with gemcitabine (GEM) in advanced pancreatic cancer (PDAC).
Chemotherapy-naive patients with locally advanced or metastatic disease were randomly assigned to receive weekly GEM 1000 mg/m(2) or GEM plus twice-weekly ET 11, 22 or 44 mg/m(2) for 7 weeks. After a safety run-in of 100 patients, a second cohort continued treatment.
End points included overall survival (OS), progression-free survival (PFS), tumor response and safety. Two hundred and twelve patients were randomly allocated to the study and 200 were treated (80% metastatic, 20% locally advanced).
Adverse events were manageable and reversible. Transient thrombocytopenia and infusion reactions with chills and pyrexia mostly grade 1 or 2 occurred in the ET groups.
Disease control rate after the first treatment cycle was 43% with GEM and 60%, 65% and 52% in the GEM + ET cohorts. Median PFS reached 2.7 compared with 4.1, 4.6 and 4.4 months, respectively.
Median OS was 6.8 compared with 8.1, 8.7 and 9.3 months, respectively. Treatment of advanced PDAC with GEM + ET was generally well tolerated.
GEM + ET showed beneficial survival and efficacy. A randomized phase III trial should confirm this positive trend.